- Home
- RIGL vs HY Comparison
RIGL vs HY Comparison
Compare RIGL & HY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | HY |
|---|---|---|
| Founded | 1996 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Construction/Ag Equipment/Trucks |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 564.7M | 640.3M |
| IPO Year | 2000 | 2012 |
Fundamental Metrics
Financial Performance| Metric | RIGL | HY |
|---|---|---|
| Price | $29.20 | $34.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $45.67 | N/A |
| AVG Volume (30 Days) | ★ 386.9K | 73.1K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 3.76% |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | $294,282,000.00 | ★ $3,769,300,000.00 |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | $12.75 | $5.29 |
| P/E Ratio | $66.97 | ★ N/A |
| Revenue Growth | ★ 64.15 | N/A |
| 52 Week Low | $18.14 | $26.41 |
| 52 Week High | $52.24 | $44.55 |
Technical Indicators
Market Signals| Indicator | RIGL | HY |
|---|---|---|
| Relative Strength Index (RSI) | 49.56 | 43.97 |
| Support Level | $28.08 | $29.68 |
| Resistance Level | $32.17 | $34.57 |
| Average True Range (ATR) | 1.99 | 2.26 |
| MACD | 0.05 | -0.56 |
| Stochastic Oscillator | 48.15 | 33.81 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About HY Hyster-Yale Materials Handling Inc.
Hyster Yale Inc designs, engineers, manufactures, sells, and services a comprehensive line of lift trucks, attachments, aftermarket parts, and technology solutions marketed globally under the Hyster and Yale brand names. The company has four segments, which include three in the lift truck business as discussed below, as well as Bolzoni S.p.A. (Bolzoni). The majority of its revenue is generated from Lift Trucks. Geographically, it operates in America, EMEA, and JAPIC regions, of which maximum revenue is generated from its business in America, which includes lift truck operations in the U.S., Canada, Mexico, Brazil, and Latin America.